Literature DB >> 18290953

Does observer bias contribute to variations in the rate of retinopathy of prematurity between centres?

Brian A Darlow1, Mark J Elder, L John Horwood, Deborah A Donoghue, David J Henderson-Smart.   

Abstract

PURPOSE: We aimed to indirectly assess the contribution from observer bias to between centre variability in the incidence of acute retinopathy of prematurity (ROP).
METHODS: The Australian and New Zealand Neonatal Network (ANZNN) collected data on the highest stage of acute ROP in either eye in 2286 infants born at less than 29 weeks in 1998-1999 and cared for in one of 25 neonatal intensive care units (NICUs). Chi-squared analysis was used to detect differences in the proportion of stages of ROP for each neonatal intensive care unit. These proportions were compared with those reported in two large studies of treatment for ROP.
RESULTS: The incidence of acute ROP in the ANZNN cohort was 42% and the ratio of stage 1:2:3 ROP was 1.5:1.9:1. There was considerable variation in both the incidence of acute ROP and the proportions with stage 1:2:3 ROP between centres. A chi-squared test determined that the assignment of stages 1, 2 and 3/4 ROP was not independent of centre (chi(2)(48) = 165.2; P < 0.0001). Treatment of stage 3 ROP varied between 15% and 120%, indicating some eyes were treated at less than stage 3.
CONCLUSION: The data are highly suggestive of observer bias contributing to the observed between centre variation in the incidence of acute ROP. In neonatal intervention studies where acute ROP is an outcome it would seem important to have an accreditation process for examining ophthalmologists, and there are similar arguments for neonatal networks which collect these data.

Entities:  

Mesh:

Year:  2008        PMID: 18290953     DOI: 10.1111/j.1442-9071.2007.01652.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  8 in total

1.  Detection of clinically significant retinopathy of prematurity using wide-angle digital retinal photography: a report by the American Academy of Ophthalmology.

Authors:  Michael F Chiang; Michele Melia; Angela N Buffenn; Scott R Lambert; Franco M Recchia; Jennifer L Simpson; Michael B Yang
Journal:  Ophthalmology       Date:  2012-04-27       Impact factor: 12.079

Review 2.  Telemedicine for retinopathy of prematurity diagnosis: evaluation and challenges.

Authors:  Grace M Richter; Steven L Williams; Justin Starren; John T Flynn; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2009-08-08       Impact factor: 6.048

3.  Real-time, computer-assisted quantification of plus disease in retinopathy of prematurity at the bedside.

Authors:  Michelle T Cabrera; Sharon F Freedman; Mary Elizabeth Hartnett; Sandra S Stinnett; Bei Bei Chen; David K Wallace
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2014 Nov-Dec       Impact factor: 1.300

4.  Accuracy of retinopathy of prematurity diagnosis by retinal fellows.

Authors:  R V Paul Chan; Steven L Williams; Yoshihiro Yonekawa; David J Weissgold; Thomas C Lee; Michael F Chiang
Journal:  Retina       Date:  2010-06       Impact factor: 4.256

Review 5.  [Risk factors and prevention of retinopathy of prematurity].

Authors:  L Pelken; R F Maier
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

6.  Validity of a telemedicine system for the evaluation of acute-phase retinopathy of prematurity.

Authors:  Graham E Quinn; Gui-shuang Ying; Ebenezer Daniel; P Lloyd Hildebrand; Anna Ells; Agnieshka Baumritter; Alex R Kemper; Eleanor B Schron; Kelly Wade
Journal:  JAMA Ophthalmol       Date:  2014-10       Impact factor: 7.389

7.  Survey on retinopathy of prematurity (ROP) in Italy.

Authors:  Cesarina Borroni; Carla Carlevaro; Sabrina Morzenti; Elena De Ponti; Valentina Bozzetti; Vito Console; Salvatore Capobianco; Paolo E Tagliabue
Journal:  Ital J Pediatr       Date:  2013-07-09       Impact factor: 2.638

8.  An international comparison of retinopathy of prematurity grading performance within the Benefits of Oxygen Saturation Targeting II trials.

Authors:  B W Fleck; C Williams; E Juszczak; K Cocker; B J Stenson; B A Darlow; S Dai; G A Gole; G E Quinn; D K Wallace; A Ells; S Carden; L Butler; D Clark; J Elder; C Wilson; S Biswas; A Shafiq; A King; P Brocklehurst; A R Fielder
Journal:  Eye (Lond)       Date:  2017-07-28       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.